Alters eligibility for Medicare price negotiations for biosimilar biological products.

This bill amends title XI of the Social Security Act to change the eligibility criteria for biosimilar biological products to participate in Medicare price negotiations. It modifies the conditions under which a biosimilar biological product can be included in the list of selected drugs for price negotiations. The bill also adjusts the delay period for including a biosimilar biological product on the list if certain conditions are met, such as pending patent litigation or the manufacturer's expectation to market the product.

Alters eligibility for Medicare price negotiations for biosimilar biological products.

This bill amends title XI of the Social Security Act to change the eligibility criteria for biosimilar biological products to participate in Medicare price negotiations. It modifies the conditions under which a biosimilar biological product can be included in the list of selected drugs for price negotiations. The bill also adjusts the delay period for including a biosimilar biological product on the list if certain conditions are met, such as pending patent litigation or the manufacturer's expectation to market the product.